查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1493340

美國mRNA合成原料市場規模、佔有率、趨勢分析報告：按類型、按應用、按最終用途、細分市場預測，2024-2030年

U.S. mRNA Synthesis Raw Materials Market Size, Share & Trends Analysis Report, By Type (Capping Agents, Nucleotides, Plasmid DNA), By Application (Vaccine, Therapeutics), By End-use, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10個工作天內

價格

美國mRNA合成原料市場成長及趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，美國mRNA合成原料市場規模將達到9.762億美元，2024年至2030年複合年成長率為2.93%。

推動市場的關鍵因素包括學術界和工業界對 mRNA 技術興趣的增加、mRNA 疫苗的優越性以及 mRNA 研究資金的增加。

隨著針對 COVID-19 疾病的 mRNA 疫苗的開發和普及，2020 年是 mRNA 技術平台的分水嶺。截至年終，5家上市mRNA平台公司市值超過150億美元。 2021 年 8 月，該市值約為 3,000 億美元。最近，受 mRNA COVID-19 疫苗成功吸引的重大投資正在推動治療多種疾病的藥物的開發。該市場是由臨床試驗的快速增加和幹細胞治療的使用增加所推動的。

此外，隨著對 mRNA 疫苗和藥品的需求增加，主要企業正在投資新設施以加強其管道和生產​​能力。例如，2021年6月，賽諾菲宣布投資約4.728億美元建立mRNA卓越中心，以加速下一代疫苗的開發和交付。同樣在2022年6月，贏創與美國政府合作，投資2.2億美元在美國建立一個新的脂質生產設施，用於基於mRNA的療法。因此，專注於 mRNA 研究的領先公司增加資金和投資預計將推動市場成長。

然而，mRNA 合成的原料是 mRNA 治療藥物合成中最昂貴的成分。此外，由於這些原料是新的，而且供應鏈並不多元化，因此提供這些關鍵原料的供應商數量有限。例如，生產 1 億劑 mRNA-1273 和 BNT162b2 預計分別需要 2.7 億美元和 1.271 億美元，阻礙了市場成長。

美國mRNA合成原料市場報告亮點

  • 封蓋劑在各類型細分市場中均佔據主導地位，2023 年銷售佔有率最大，為 41.02%。封端劑可作為結合分子和穩定劑，以防止空間位阻和聚集。因此，封端劑在 mRNA 合成中的這些關鍵功能正在推動這一領域的發展。
  • 按應用分類，疫苗製造佔據最大的收益市場佔有率， 2023年為83.86%。癌症、呼吸道疾病、心臟疾病和 CKD 等慢性疾病的盛行率不斷上升，促使科學家利用 mRNA 技術來發現新的、更有效的疫苗。
  • 按最終用途分類，生物製藥和製藥公司在這一領域佔據主導地位，2023 年收益佔有率為 49.56%，預計在預測期內將以最高複合年成長率成長。這是因為市場新興企業已經加入多個聯盟，以增強其 mRNA 合成原料的供應。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章美國mRNA合成原料市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 市場問題分析
  • 產業分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19 影響分析

第4章美國mRNA合成原料市場：類型預估及趨勢分析

  • 類型細分儀表板
  • 美國mRNA合成原料市場類型波動分析
  • 2018-2030年美國mRNA合成原料市場規模及趨勢分析（依類型）
  • 封端劑
  • 核苷酸
  • 質體DNA
  • 酵素
  • 其他

第5章美國mRNA合成原料市場：應用預估及趨勢分析

  • 使用細分儀表板
  • 美國mRNA合成原料市場應用變化分析
  • 2018-2030年美國mRNA合成原料市場規模及趨勢分析（依應用）
  • 疫苗生產
  • 治療藥物製造
  • 其他

第6章美國mRNA合成原料市場：最終用途估算及趨勢分析

  • 最終用途細分儀表板
  • 美國mRNA合成原料市場最終用途變化分析
  • 2018-2030年美國mRNA合成原料市場規模及趨勢分析（依最終用途）
  • 生物製藥和製藥公司
  • 合約研究官（CRO）和首席行銷長（CMO）
  • 學術研究所

第7章 競爭格局

  • 公司分類
  • 策略規劃
  • 2023 年企業市場分析
  • 公司簡介/名單
    • F. Hoffmann-La Roche Ltd.
    • Jena Bioscience GmbH
    • Merck KGaA
    • Yeasen Biotechnology（Shanghai）Co., Ltd
    • BOC Sciences
    • Thermo Fisher Scientific, Inc.
    • Maravai LifeSciences
    • New England Biolabs
    • Creative Biogene
    • HONGENE
    • Evonik Industries AG
    • GENEVANT SCIENCES CORPORATION
Product Code: GVR-4-68040-283-7

U.S. mRNA Synthesis Raw Materials Market Growth & Trends:

The U.S. mRNA synthesis raw materials market size is anticipated to reach USD 976.2 million by 2030 and is growing at a CAGR of 2.93% from 2024 to 2030, according to a new report by Grand View Research, Inc. The major factors driving the market include growing academic & industrial interest in mRNA technology, advantages of mRNA vaccines, and increasing funding for mRNA research.

The development and widespread application of mRNA vaccines for the COVID-19 disease made 2020 a watershed year for mRNA technology platforms. At the end of 2019, the market value of the five publicly traded mRNA platform companies was over USD 15 billion. This capitalization was about USD 300 billion in August 2021. Recent major investment has been attracted due to the success of mRNA's COVID-19 vaccines, promoting the creation of medications to treat numerous diseases. The upsurge in clinical trials and the growing use of stem cell therapies drive the market.

Moreover, key players are investing in new facilities to enhance their pipeline and production capabilities owing to rising demand for mRNA vaccines and medicines. For instance, in June 2021, Sanofi announced an investment of approximately USD 472.8 million to build the mRNA Center of Excellence to accelerate developing and delivering next-generation vaccines. In addition, in June 2022, Evonik, in partnership with the U.S. government, invested USD 220 million to build a new lipid production facility in the U.S. for mRNA-based therapies. Hence, increasing funding and investments by major players to focus on mRNA research is anticipated to drive market growth.

However, raw materials for mRNA synthesis are the most expensive component for the synthesis of mRNA therapeutics. In addition, these raw materials are new and lack a diversified supply chain, with a limited number of suppliers providing these vital materials. For instance, manufacturing 100 million doses of mRNA-1273 and BNT162b2 was estimated to cost USD 270 million and USD 127.1 million, respectively, thus hampering market growth.

U.S. mRNA Synthesis Raw Materials Market Report Highlights:

  • Capping agents dominated the type segment with the largest revenue share of 41.02% in 2023. Capping agents function as binding molecules or stabilizers, preventing steric hindrance or agglomeration. Hence, these key functions of capping agents in mRNA synthesis are driving the segment
  • Based on the application, vaccine production held the largest revenue market share of 83.86% in 2023. The rising prevalence of chronic diseases, such as cancer, respiratory disorders, cardiac diseases, CKD, and many others, is encouraging scientists to discover novel as well as more effective vaccines using mRNA technology
  • Based on end-use, biopharmaceutical & pharmaceutical companies dominated the segment with a revenue share of 49.56% in 2023 and is anticipated to grow at the highest CAGR over the forecast period. This is attributed to the emerging companies in the market entering several collaborations to enhance their mRNA synthesis raw materials offerings

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Type Segment
    • 1.1.2. Application Segment
    • 1.1.3. End-use Segment
  • 1.2. Estimates and Forecast Timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Primary Research
  • 1.5. Information or Data Analysis:
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. Objective

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. mRNA Synthesis Raw Material Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing academic & industrial interest in mRNA technology
      • 3.2.1.2. Advantages of mRNA vaccines
      • 3.2.1.3. Increasing funding for mRNA research
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Nonexistence of effective government regulations for mRNA-based product approvals
      • 3.2.2.2. High cost of mRNA synthesis raw materials
    • 3.2.3. Market Challenge Analysis
      • 3.2.3.1. Lack of long-lasting and affordable manufacturing processes
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. U.S. mRNA Synthesis Raw Material Market: Type Estimates & Trend Analysis

  • 4.1. Type Segment Dashboard
  • 4.2. U.S. mRNA Synthesis Raw Materials Market Type Movement Analysis
  • 4.3. U.S. mRNA Synthesis Raw Materials Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Capping Agents
    • 4.4.1. Capping Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Nucleotides
    • 4.5.1. Nucleotides Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Plasmid DNA
    • 4.6.1. Plasmid DNA Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Enzymes
    • 4.7.1. Enzymes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.7.2. Polymerase
      • 4.7.2.1. Polymerase Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.7.3. RNase Inhibitor
      • 4.7.3.1. RNase Inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.7.4. DNase
      • 4.7.4.1. DNase Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.7.5. Others
      • 4.7.5.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. mRNA Synthesis Raw Material Market: Application Estimates & Trend Analysis

  • 5.1. Application Segment Dashboard
  • 5.2. U.S. mRNA Synthesis Raw Materials Market Application Movement Analysis
  • 5.3. U.S. mRNA Synthesis Raw Materials Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Vaccine Production
    • 5.4.1. Vaccine Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Therapeutics Production
    • 5.5.1. Therapeutics Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. mRNA Synthesis Raw Material Market: End-use Estimates & Trend Analysis

  • 6.1. End-use Segment Dashboard
  • 6.2. U.S. mRNA Synthesis Raw Materials Market End-use Movement Analysis
  • 6.3. U.S. mRNA Synthesis Raw Materials Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
  • 6.4. Biopharmaceutical & Pharmaceutical Companies
    • 6.4.1. Biopharmaceutical & Pharmaceutical Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. CROs & CMOs
    • 6.5.1. CROs & CMOs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Academic & Research Institutes
    • 6.6.1. Academic & Research Institutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Strategy Mapping
  • 7.3. Company Market Position Analysis, 2023
  • 7.4. Company Profiles/Listing
    • 7.4.1. F. Hoffmann-La Roche Ltd.
      • 7.4.1.1. Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. Jena Bioscience GmbH
      • 7.4.2.1. Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. Merck KGaA
      • 7.4.3.1. Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. Yeasen Biotechnology (Shanghai) Co., Ltd
      • 7.4.4.1. Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. BOC Sciences
      • 7.4.5.1. Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. Thermo Fisher Scientific, Inc.
      • 7.4.6.1. Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. Maravai LifeSciences
      • 7.4.7.1. Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. New England Biolabs
      • 7.4.8.1. Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. Creative Biogene
      • 7.4.9.1. Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. HONGENE
      • 7.4.10.1. Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Strategic Initiatives
    • 7.4.11. Evonik Industries AG
      • 7.4.11.1. Overview
      • 7.4.11.2. Financial Performance
      • 7.4.11.3. Product Benchmarking
      • 7.4.11.4. Strategic Initiatives
    • 7.4.12. GENEVANT SCIENCES CORPORATION
      • 7.4.12.1. Overview
      • 7.4.12.2. Financial Performance
      • 7.4.12.3. Product Benchmarking
      • 7.4.12.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviation
  • Table 3 U.S. mRNA synthesis raw materials market, by type, 2018 - 2030 (USD Million)
  • Table 4 U.S. mRNA synthesis raw materials market, by application, 2018 - 2030 (USD Million)
  • Table 5 U.S. mRNA synthesis raw materials market, by end-use, 2018 - 2030 (USD Million)
  • Table 6 Key companies undergoing expansions
  • Table 7 Key companies undergoing acquisitions
  • Table 8 Key companies undergoing collaborations
  • Table 9 Key companies launching new products/services
  • Table 10 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 U.S. mRNA synthesis raw materials market: market outlook
  • Fig. 7 U.S. mRNA synthesis raw materials competitive insights
  • Fig. 8 Parent market outlook
  • Fig. 9 U.S. mRNA synthesis raw materials market driver impact
  • Fig. 10 U.S. mRNA synthesis raw materials market restraint impact: Type & services movement analysis
  • Fig. 11 U.S. mRNA synthesis raw materials market: Type outlook and key takeaways
  • Fig. 12 Capping agents market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 13 Nucleotides market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 14 Plasmid DNA market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 15 Enzymes market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 16 Polymerase market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 17 RNase inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 DNase materials market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Others market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 21 U.S. mRNA synthesis raw materials market: Application movement analysis
  • Fig. 22 U.S. mRNA synthesis raw materials market: Application outlook and key takeaways
  • Fig. 23 Vaccine production market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Therapeutics production market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Others application market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 U.S. mRNA synthesis raw materials market: End-use movement analysis
  • Fig. 27 U.S. mRNA synthesis raw materials market: End-use outlook and key takeaways
  • Fig. 28 Biopharmaceutical & pharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 CROs CMOs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Academic & research institutes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Market share of key market players - U.S. mRNA synthesis raw materials market